TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Berubicin Program Forward

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments, recently announced that the first patient in Europe had been enrolled and dosed in France in the company’s ongoing global trial to evaluate Berubicin for the treatment of recurrent glioblastoma multiforme (“GMB”), an aggressive and incurable form of brain cancer. “Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier (based upon pre-clinical and limited clinical data) and is currently being evaluated in the potentially pivotal study evaluating efficacy and safety for GBM treatment. This study is an adaptive, multicenter, open-label, randomized, and controlled study in adults with recurrent GBM after the failure of standard first-line therapy,” a recent article reads. “CNS Pharmaceuticals has opened 29 clinical sites of the 68 selected across the United States, Italy, France, Spain, and Switzerland… According to CEO John Climaco, the CNS Pharmaceuticals team worked tirelessly to expand its Berubicin clinical trial globally, and the enrollment and dosing of the first patient in France shortly after the opening of the site is a notable accomplishment and confirmation of the team’s commitment to driving the program forward.”

To view the full article, visit https://ibn.fm/e3ppj

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com

TinyGems is part of the InvestorBrandNetwork

Alex Pearon

Share
Published by
Alex Pearon
Breaks Categories: Stock Spotlights

Recent Posts

TinyGemsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Secures Roles in Two U.S. Army Microgrid Projects Valued at $144.6 Million

AZIO AI Holdings (NASDAQ: AZIO), a developer of power infrastructure for artificial intelligence ("AI") campuses,…

2 days ago

TinyGemsBreaks – ZenaTech, Inc. (NASDAQ: ZENA) (FSE: 49Q) (BMV: ZENA) Surpasses C$20 Million in Contracted Revenue Backlog Across Global Operations

ZenaTech (NASDAQ: ZENA) (FSE: 49Q) (BMV: ZENA) announced that its consolidated contracted revenue backlog has…

3 days ago

TinyGemsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Signs Agreement to Support $144.6 Million in U.S. Army Microgrid Contracts

AZIO AI Holdings (NASDAQ: AZIO) announced it has signed a general contracting agreement with Energy…

3 days ago

TinyGemsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Establishes Space and Government Power Team to Pursue Lunar and Defense Infrastructure Opportunities

AZIO AI Holdings (NASDAQ: AZIO) announced the formation of a dedicated space and government power…

4 days ago

TinyGemsBreaks – ZenaTech, Inc. (NASDAQ: ZENA) (FSE: 49Q) (BMV: ZENA) Secures Energy Sector Survey Contracts With Potential Follow-On Work Totaling Nearly C$1 Million

ZenaTech (NASDAQ: ZENA)  (FSE: 49Q) (BMV: ZENA) announced that its Drone as a Service ("DaaS")…

5 days ago